Answers are grounded in this paper and cite their sources.
Cuproptosis has attracted great attention for current cancer therapy because it can boost antitumor immune responses by triggering immunogenic cell death (ICD). However, the efficiency of inducing cuproptosis in tumor cells is quite low due to a poor efficiency in targeted delivery of copper ions, a preferential metabolic pathway of glycolysis in tumor cells, protective mechanisms of intracellular redox homeostasis, and copper homeostasis regulatory mechanisms mediated by ATP7A for copper efflux. Herein, Cu 2+ was chelated with dicoumarol, a dual inhibitor for pyruvate dehydrogenase kinase 1 (PDK1) and NAD(P)H: quinone oxidoreductase 1 (NQO1), to form a lipophilic complex (DC), which sensitized tumor cells to cuproptosis by inhibiting glycolysis and disrupting redox homeostasis. Moreover, DC was encapsulated with a conjugate (PR) of PEG and retinoic acid (RA). RA destroyed the structure and function of the Golgi apparatus, thus blocking the translocation of ATP7A from the Golgi apparatus to the plasma membrane to prevent copper efflux. The obtained cuproptosis-inducing system (PRDC) efficiently targeted tumor sites and potently induced cuproptosis in tumor cells through metabolic and homeostatic regulatory strategies, providing a new strategy for intervening in the copper efflux mechanism and amplifying cuproptosis for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: